After failed clinical trial, aging-focused drug company Unity Bio to cut staff by 30%

The company will concentrate on ophthalmology and neurology and start an early-stage clinical trial in diabetic macular edema yet this year.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.